Interference of Home Blood Glucose Measurements and Poor Outcomes: A Solvable Problem Requiring Broader Exposure

Hirsch IB . Blood glucose monitoring technology: translating data into practice. Endocr Pract, 2004; 10:67–76.

Hirsch IB , Bode BW , Childs BP , Close KL , Fisher WA , Gavin JR , Ginsberg BH , Raine CH , Verderese CA . Self-monitoring of blood glucose (SMBG) in insulin- and non-insulin-using adults with diabetes: consensus recommendations for improving SMBG accuracy, utlization, and research. Diabetes Technol Ther, 2008; 10:419–439.

FDA Public Health Notification: Potentially Fatal Errors with GDH-PQQ Glucose Monitoring Technology. August 13, 2009. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm176992.htm. 2009 August 30.

Janssen W , Harff G , Caers M , Schellekens A . Positive interference of icodextrin metabolites in some enzymatic glucose methods. Clin Chem, 1998; 44:2379–2380.

ISMP Medication Safety Alert. Be Aware of False Glucose Results with Point-of-Care Testing. 2005;10:13. http://www.ismp.org/Newsletters/acutecare/articles/20050908.asp?ptr=y. 2009 August 30.

ISMP Erratum: Important Safety Information on Interference With Blood Glucose Measurement Following Use of Parenteral Maltose/Parenteral Galactose/Oral Xylose-Containing Products. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm154213.htm. 2009 August 30.

MHRA: MDA/2007/058—Point of Care and Home-Use Blood Glucose Meters: Roche Accu-Chek and Glucotrend; Abbott Diabetes Care FreeStyle. http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON2031807. 2009 August 30.

Gaines AR , Pierce LR , Bernhardt PA . Fatal Iatrogenic Hypoglycemia: Falsely Elevated Blood Glucose Readings with a Point-of-Care Meter Due to a Maltose-Containing Intravenous Immune Globulin Product. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm155099.htm. 2009 August 30.

Abbott Diabetes Care: Important Safety Information: Glucose Monitoring and Interfering Substances. http://abbottdiabetescare.com/adc_dotcom/url/content/en_US/30.50:50/general_content/General_Content_0000410.htm. 2009 August 30.

Roche Diabetes Care: Important Information—FDA Public Health Notification. http://www.aace.com/alert/RochePatientLetter.pdf. 2009 August 30.

Nissen SE , Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med, 2007; 356:2457–2471.

Smith U , Gale E . Does diabetes therapy influence the risk of cancer? Diabetologia, 2009; 52:1699–1708.